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The vertebrate immune system is poised in a state of equilibrium that permits accurate and rapid
protective responses against pathogens but curtails potential for causing harm to the host through
targeting of ‘‘self’’ and provoking overexuberant inflammatory processes. In this Review we discuss
this balance achieved in large part by interactions of different classes of T lymphocytes that
have potent pro- or anti-inflammatory activity in the context of genetic and environmental factors,
particularly the commensal microbiota.Introduction
Innate immune systems of lower organisms afford protection
against infection through recruitment and activation of phago-
cytic effector cells and through elaboration of soluble mediators.
The innate immune defenses are summoned upon recognition of
microbial products by conserved, germline encoded sensors
selected during evolution for their ability to recognize prototyp-
ical molecular features or patterns distinguishing microorgan-
isms from their hosts (Janeway, 1989). These sensing mecha-
nisms are exemplified by Toll-like receptors (TLR) and their
ligands, including lipopolysaccharide (LPS), lipopeptide, and
bacterial and viral nucleic acids (Medzhitov, 2009). Changes in
the metabolic status of the host caused by the infectious agents
or damage to the host tissues can also be detected by additional
sets of sensors such as the inflammasome. Recent advances in
understanding of molecular and cellular mechanisms of infec-
tion-associated inflammation are discussed in detail in Reviews
by O. Takeuchi and S. Akira and K. Schroder and J. Tschopp
(page 805 and page 821 of this issue, respectively). During
the last several years it has become apparent that these sens-
ing mechanisms are capable of distinguishing different classes
of pathogens and are hard-wired to activate distinct effectors
capable of protection against the corresponding type of
pathogen.
The effectiveness of innate immune defenses is limited in
higher organisms, likely due to the complexity of the body plan
along with delayed onset and decreasing rate of reproduction,
which result in steeper evolutionary penalties for failures of
the immune system. Adaptive immune systems, which rely on
the somatic generation of enormously diverse antigen-specific
receptors, have thus evolved to anticipate encounters with
invading pathogens and to effectively counter the rapid evolution
of viruses and bacteria facilitated by their high reproduction and
mutation rates. Two branches of adaptive immune recognition,
mediated by T cell receptors (TCRs) and immunoglobulin (Ig)
receptors utilized by T and B lymphocytes, are directed against
pathogens hidden within the cells of the host or exposed forrecognition outside the host cells or on their surfaces, respec-
tively.Whereas Ig receptors displayed by B cells recognize intact
antigens, T cell receptors recognize short peptides derived from
foreign and self-antigens bound to products of highly polymor-
phic major histocompatibility complex (MHC) molecules. MHC
molecules present peptide products of constitutive cellular
protein breakdown and do not distinguish between self and
foreign, i.e., pathogen-derived products, and hence their recog-
nition by TCRs underlies the central roles that T cells have in both
host defense and autoimmune inflammatory diseases. T cells
must exist in a balanced state in which they are poised to pounce
on offending microbes while remaining tolerant to host mole-
cules and harmless commensal microorganisms. How T cells
achieve a state of tolerance to self-antigens and how patholog-
ical conditions, environmental factors, and genetic predisposi-
tion result in breaking of tolerance and establishment of inflam-
matory processes have been areas of intense investigation
during the past two decades. It is now known that, in addition
to central tolerance established as a result of induced apoptosis
of strongly self-reactive cells in the thymus, there are mecha-
nisms of peripheral tolerance, achieved in large part through
the activity of regulatory T (Treg) cells.
Distinct types of adaptive immune responses affording pro-
tection against different classes of pathogens are facilitated
by the differentiation of CD4+ T cells into the corresponding
types of effector T cells, which currently include Th1, Th2, and
Th17 subsets. Through elaboration of distinct sets of cytokines
and other soluble and cell-bound products, these cells may act
as immune effectors eliminating infected cells. More importantly,
they act as principal amplifiers and inducers of the appropriate
inflammatory and effector responses in cells of the innate
immune system and ‘‘nonimmune’’ cells. The amplified blocks
of adaptive and innate immune responses lead to efficient clear-
ance or containment of the offending pathogen.
The downside of powerful mechanisms of protection against
pathogen afforded by the immune system of higher organisms
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responses against ‘‘self’’ and environmental antigens and com-
mensal microorganisms as well as ‘‘collateral’’ damage to the
host as a side effect of immune responses against pathogens.
These side effects are at times more devastating than infection
itself. Thus, protective immune responses must ensure survival
of the host in a trade-off between sterilizing immunity and its
negative regulation limiting pathogen elimination. The restraint
of overzealous immune responses involves numerous mecha-
nisms operating in a cell-intrinsic and -extrinsic manner in rela-
tion to inflammation-inducing cells. Among these mechanisms,
Treg cell-mediated suppression of inflammation associated
with infection plays a prominent role.
In this Review, we discuss T cell-mediated inflammation and
the mechanisms of its negative regulation by focusing on differ-
entiation and function of Th17 effector cells, which elicit a highly
inflammatory immune response, and of Treg cells that serve as
critical gatekeepers in immune homeostasis. Th17 cells have
been implicated in numerous autoimmune diseases and other
inflammatory conditions, but they, as well as Treg cells, are
most abundant at mucosal surfaces, particularly the intestinal
lamina propria (LP). We will highlight recent studies linking
signals from commensal microbes to the differentiation and
function of these types of T cells.Th17 Cells and Company
Following infection with diverse microbes, T cells undergo differ-
entiation when their TCRs are triggered in the presence of partic-
ular combinations of cytokines produced by innate immune cells
(Abbas et al., 1996; Mosmann and Coffman, 1989). Infection of
myeloid cells with intracellular bacteria and viruses typically
elicits production of IL-12, which induces differentiation of inter-
feron-g (IFN-g)-producing Th1 cells and cytotoxic CD8+ T cells
that are best suited to clear such pathogens. Infection with para-
sitic worms, in contrast, induces production of IL-4 by cells of the
innate immune system, and this, in turn, stimulates CD4+ T cells
to differentiate into Th2 cells that produce more IL-4, as well as
IL-5 and IL-13, cytokines involved in controlling expulsion of
the helminths.
A third subset of T helper cells, Th17 cells, are abundant at
mucosal interfaces, where they contain infection with patho-
genic bacteria and fungi (Weaver et al., 2007). These cells
produce IL-17A (also referred to as IL-17), IL-17F, and IL-22,
cytokines involved in neutrophilia, tissue remodeling and repair,
and production of antimicrobial proteins. Since IL-17 cytokine
family members are found in invertebrate organisms, where
they appear to be involved in immune responses, Th17 cells
may represent a relatively recent evolutionary adaptation of
T cells to employ an effector program that predates the branch-
ing of chordates (Guo et al., 2009; Hibino et al., 2006; Roberts
et al., 2008).
Th17 cells differentiate in response to the STAT3-activating
cytokines IL-6, IL-21, and IL-23 along with TGF-b and IL-1b
(Korn et al., 2009). Skin-homing T helper cells that produce
IL-22, but not IL-17, have been described in humans, and it is
possible that they represent a T cell subset with distinct effector
functions (Duhen et al., 2009). The differentiation of CD4+ T cells
that produce IL-17 and IL-22 is influenced by the composition of846 Cell 140, 845–858, March 19, 2010 ª2010 Elsevier Inc.the intestinal microbiota and by the presence of innate immune
cells that amplify the Th17 cell response.
Th1 cells were long considered to be the major effectors in
multiple autoimmune diseases, while Th2 cells have been known
to be involved in atopy and asthma. More recently, Th17 cells
have been implicated as culprits in a plethora of autoimmune
and other inflammatory diseases in mice and humans. Many of
the disease states previously associated with Th1 cells, e.g.,
experimental autoimmune encephalomyelitis (EAE, a model for
multiple sclerosis), collagen-induced arthritis, and some forms
of colitis, were shown to be caused by IL-23-dependent Th17
cells or other IL-17-producing lymphoid cell types (Ahern et al.,
2008; Cua et al., 2003; McKenzie et al., 2006). An imbalance
between Th17 and Treg cell function may be central in some of
these diseases. Conversely, defects in the Th17 cell differentia-
tion axis may predispose the host to bacterial and fungal infec-
tions at mucosal surfaces (Ouyang et al., 2008).
Differentiation of Th17 Cells
The existence of Th17 cells was only recently appreciated,
following the discovery that the p40 subunit of IL-12 and its
receptor subunit, IL-12Rb1, are shared by IL-23 and its receptor,
respectively. Selective inactivation of the p19 component of
IL-23 or the IL-23 receptor resulted in loss of autoimmune
disease manifestations, increased susceptibility to infections
with mucosal pathogens, and marked reductions in the number
ofCD4+ T cells expressing IL-17 and, especially, IL-22 (McKenzie
et al., 2006; Ouyang et al., 2008). Th17 cells were shown to differ-
entiate in vitro from naive CD4+ T cells in response to TCR
signaling in the presence of IL-6 and TGF-b, but not IL-23 (Bettelli
et al., 2006; Veldhoen et al., 2006). The receptor for IL-23 is ex-
pressed on naive murine CD4+ T cells only after stimulation in
the presence of IL-6 or IL-21, and then these other cytokines
cangiveway to the ability of IL-23 to stimulate continueddifferen-
tiation of Th17 cells and, perhaps, their survival (Korn et al., 2007;
Nurieva et al., 2007; Zhou et al., 2007). In human T cells, IL-23R
may be constitutively expressed on CD4+ T cells, and hence
IL-17 expression can be induced by IL-23 in vitro (Manel et al.,
2008). Mouse T cells bearing gd TCRs, which are prominent in
mucosal tissues, also express IL-23R constitutively and have
been reported to differentiate into IL-17-producing cells early
after exposure to IL-23 (see below) (Roark et al., 2008).
Whether Th17 cells represent a true terminally differentiated
lineage versus a metastable state with distinct effector functions
has been an area of much recent investigation. Many IL-17+ cells
present in inflammatory foci, for example in the central nervous
system of mice with EAE, also express IFN-g, and there is
evidence that IL-17+ T cells can differentiate into Th1 cells under
inflammatory conditions in vivo (Bending et al., 2009). Th1 and
Th2 cells were thought to be more stable, but recent studies
found that Th2 cells can be induced to also express T-bet, the
central transcriptional regulator for Th1 cells, and IFN-g following
infection with viruses (Hegazy et al., 2010). Thus, reprogramming
of T helper cell effector functions may be critical for host defense
to specific microbial challenge. In this context, studies of the
epigenetic status of the genes that encode lineage-restricted
transcription factors have been invoked as providing insight as
to the reprogramming capacity of T cells. However, in vitro
Figure 1. Role of Innate Lymphocytes in Initiation and Amplification
of a Th17 Cell Response
Early activation of innate immune cells through their pattern recognition recep-
tors (PRRs) results in production of IL-1b and IL-23 that, together, induce IL-17
production in gd T cells (and potentially other RORgt+ lymphocytes) in the
absence of TCR signaling. IL-17 induces production of inflammatory cytokines
by epithelial and stromal cells, and these amplify responses by acting on TCR-
activated CD4+ T cells and on other innate lymphocytes.polarized Th2 and Th17 cells displayed repressive histone modi-
fications at the Tbx21 locus encoding T-bet, rather than the biva-
lent configuration of positive and negative marks thought to
represent a state poised for reprogramming. Thus, the chromatin
state in these cells does not appear to reflect the differentiation
potential observed in vivo. The epigenetic status of regulatory
genes in T cells recovered directly from animals has yet to be
determined. It may not be surprising if the gene expression
state of multiple loci differs in T cells according to their site in
the body and the type of inflammatory or microbial challenge
confronted.
The Th17 program, whether stable or not, is defined both
in vitro and in vivo by the expression of the signature cytokines,
the chemokine receptor CCR6, and IL-23R. These same features
are also found in other lymphoid cells, e.g., TCRgd T cells,
lymphoid tissue inducer (LTi) cells, and phenotypically related
cells with NK cell markers, that secrete IL-17 and/or IL-22
(Colonna, 2009). These cells sharewith Th17 cells the expression
of the orphan nuclear receptor RORgt, which is both necessary
and sufficient for expression of the genes that currently define
the Th17 program (Ivanov et al., 2006). In addition to RORgt,
multiple other transcription factors (TFs) have been shown to
be required for the expression of IL-17 in polarized T helper
cells, and several of these are also required for upregulation of
RORgt upon polarization. These include IRF4 and BATF, whose
expression is induced upon TCR signaling, and STAT3 (Brustle
et al., 2007; Schraml et al., 2009; Zhou and Littman, 2009). Addi-
tional transcription factors that contribute to the induction of
IL-17 in polarized cells include Runx1/CBFb, c-Maf, and the
ligand-regulated aryl hydrocarbon receptor (Ahr) (Bauquet et al.,
2009; Veldhoen et al., 2008; Zhang et al., 2008). RORa also
contributes to some IL-17 expression in the absence of RORgt
(Yang et al., 2008b). Except for Ahr, which is required for induc-
tion of IL-22 in response to xenobiotic ligands, the role of most of
these factors in establishing a Th17 gene signature other than
IL-17 itself has not been examined. STAT3, IRF4, and BATF
are required for expression of RORgt in Th17-polarized T helper
cells, yet each contributes additionally, in cooperation with
RORgt, to expression of IL-17 and, likely, other key components
of the Th17 program. The genetic underpinning of the program
will likely be unraveled through a combination of high-throughput
ChIP-sequence analysis and expression profiling of T cells with
mutations in the different TF genes.
The expression of IL-17 by at least one lymphocyte subset, the
gd T cells, has been proposed to be important for Th17 cell differ-
entiation. Unlike Th17 cells, which produce IL-17 in response to
TCR and cytokine receptor stimulation, the gd T cells do so
independently of the TCR upon exposure to IL-23 and IL-1b (Sut-
ton et al., 2009; Roark et al., 2008). The gd cells produce IL-17
in vivo within hours following infection or other inflammatory
stimuli, likely due to the presence of the inducing cytokines
as well as stimulation of cell surface TLRs and dectin1 by micro-
bial products (Martin et al., 2009). IL-17 then activates widely
expressed receptors, on mesenchymal and epithelial cells,
resulting in production of IL-6, IL-1b, and other inflammatory
cytokines that act in a positive feedback loop on the gd cells
and on differentiating Th17 cells (Figure 1). Mice deficient for
gd cells have markedly attenuated Th17-mediated autoimmunedisease, consistent with a need for this amplifying loop in the
induction of pathogenic Th17 cells (Sutton et al., 2009).
Th17 Cells in Inflammation
Although there is abundant evidence that Th17 cells have impor-
tant roles in a variety of inflammatory conditions, there is consid-
erable controversy as to whether the key cytokines produced
by these cells are essential in those diseases. It also remains
unclear what is the relative contribution to host protection and
inflammation of the diverse cell types that have an effector cyto-
kine profile similar to that of Th17 cells. IL-17, IL-17F, and IL-22
have been shown to be required to protect mice from pathology
induced by air-borne Klebsiella pneumoniae and orally adminis-
tered Citrobacter rodentium (Ouyang et al., 2008). However, the
roles of these cytokines in several autoimmune disease models
have been disputed. Thus, IL-17 and/or IL-17F deficiency does
not prevent colitis mediated by transfer of Treg-depleted CD4+
T cells (Izcue et al., 2008; Leppkes et al., 2009), and colitis may
even be exacerbated in the absence of IL-17 receptor signaling
in pathogenic Th1 cells (O’Connor et al., 2009), presumably due
to elevated IFN-g. Although IL-17 was reported to have an
important role in EAE (Komiyama et al., 2006), more recent
reports have disputed that assertion and also showed no signif-
icant contribution of IL-22 (Haak et al., 2009; Kreymborg et al.,
2007). However, multiple genetic studies have shown that IL-23
and its receptor as well as RORgt, which are essential for
the differentiation of Th17 cells, are required for diseaseCell 140, 845–858, March 19, 2010 ª2010 Elsevier Inc. 847
manifestation in the colitis and EAEmodels (Cua et al., 2003; Iva-
nov et al., 2006; Kullberg et al., 2006; Uhlig et al., 2006). More-
over, polymorphisms in the IL-23R gene have been strongly
associated with either protection from or susceptibility to
Crohn’s disease (Abraham and Cho, 2009). These apparently
conflicting observations have two nonmutually exclusive expla-
nations: there are effector functions other than production of
the signature cytokines that contribute to inflammationmediated
by Th17 cells; and other lymphoid cell types that are dependent
on IL-23R signaling and RORgt may have pivotal roles in
licensing T cell effector functions that result in inflammatory
disease. The functions of such cells have not been studied in
great detail, but IL-17 produced by gd T cells, LTi cells, and
NK-like cells may function to amplify Th17 effector functions.
In this context, it remains difficult to assess relative contributions
of Th17 cells versus other IL-23-dependent cells to inflammatory
responses at mucosal sites. Selective inactivation of IL-23R and/
or RORgt in different cell subsets will be required to clearly
demarcate the functions of each cell type in mounting Th17
responses and in mediating both antimicrobial defense and
inflammatory disease.
Th17-associated cytokines, if not Th17 cell per se, have been
implicated as contributing to metabolic diseases and cancer.
IL-23 and IL-17 have been shown to contribute to colon carcino-
genesis in mice that had the multiple polyposis Apcmin mutation
and that were colonized with enterotoxigenic Bacteroides fragi-
lis, a bacterium present in the gut flora of a sizeable fraction of
humans and associated with diarrhea (Wu et al., 2009). IL-23
has also been shown to promote the growth of multiple tumors
in mice, particularly chemically induced papillary skin tumors
(Langowski et al., 2006). A contribution of IL-17 to atheroscle-
rotic disease has been proposed, but a direct link to Th17 cells
or other inflammatory lymphocytes has not yet been established
(Taleb et al., 2009). Diet-induced obesity in mice has been
reported to result in an IL-6-dependent increase in Th17 cells,
and the metabolic imbalance may thus contribute to increased
severity or incidence of autoimmune disease (Winer et al.,
2009). The positive amplifying loop in induction of Th17 cyto-
kines suggests that, in the absence of countervailing regulation,
e.g., production of IL-10 or Treg cells, Th17 cells may indeed
contribute to the onset or persistence of metabolism-associated
diseases.
Role of the Microbiota in T Cell Differentiation
and in Maintenance of Barrier Function
Inflammatory responses are influenced by microbial products
encountered during infections with pathogens and by host
genetic polymorphisms that may predispose individuals to auto-
immune disease. In addition, the commensal microbiota have
a particularly important influence in regulating the immune sys-
tem. Products of commensal microbes are likely to contribute
to distribution of lymphoid cells in different mucosal tissues
and to their effector functions, which protect against damage
inflicted on the tissue by pathogens or toxins. Naive T lympho-
cytes receive innate immune cell-derived signals that guide
them to specific tissues. Thus, DC-derived vitamin D and retinoic
acid induce, respectively, CCR10 and CCR9, whose engage-
ment by chemokines guides the T cells to skin and small intes-848 Cell 140, 845–858, March 19, 2010 ª2010 Elsevier Inc.tine, respectively (Iwata et al., 2004; Sigmundsdottir et al.,
2007). T cells that traffic to the intestine typically have effector
or memory cell phenotypes, indicative of their previous exposure
to antigenic stimuli. Such cells are present in large numbers in
both large intestine and the terminal ileum, sites of extensive
organized lymphoid tissue. These are also sites of abundant
colonization with hundreds of different bacterial species that
make up the commensal microbiota. The contribution of the
microbiota to host immune responses has long been recog-
nized, but it is only recently that specific bacterial species have
been linked to the differentiation of specific types of T cells.
The composition of the gut microbes has also been shown to
correlate with proclivity for obesity or type 2 diabetes (Blaser
and Falkow, 2009; Turnbaugh and Gordon, 2009), but it is not
known whether microbial influence on T cells has a function in
these metabolic disorders.
Th17 and Treg cells are most abundant in the intestinal LP.
TCR transgenic, RAG-deficient mice have all T cells restricted
to a single specificity and typically lack LP T cells. However,
they accumulate such cells if they are fed antigen that is pro-
cessed to be recognized by the transgenic TCR (Curotto de
Lafaille and Lafaille, 2009). The specificity of the LP T cells
present in mice with a full TCR repertoire is not currently known,
although it is likely that many of the T cells are specific for prod-
ucts of the commensal microbiota. Nevertheless, the number of
T cells in the LP is only modestly reduced in mice kept in germ-
free conditions, which suggests that T cells accumulate due to
activation in response to self and/or food antigens. In addition
to antigenic stimuli, other commensal-derived signals influence
the differentiation of T cells with distinct effector functions.
Thus, colonization of mice with polysaccharide-A (PSA)-defi-
cient Bacteroides fragilis, a commensal present in humans,
promoted colitis in RAG-deficient mice into which Treg-depleted
naive CD4+ T cells had been transferred. However, administra-
tion of PSA protected the mice from transfer-mediated colitis,
and this correlated with an increase in production of IL-10 and
reduced levels of IFN-g and IL-17 in colonic T cells (Mazmanian
et al., 2008). PSA has therefore been proposed to be a com-
mensal product that modulates the balance between inflamma-
tory T cells and regulatory functions, e.g., IL-10, although it is not
yet known whether discrete T cell subsets produce this regula-
tory cytokine. Indeed, it is now clear that all effector CD4+
T cell subsets, including Foxp3+ Treg cells, can produce IL-10
under appropriate conditions (Li and Flavell, 2008; Saraiva
et al., 2009).
Segmented filamentous bacterium (SFB) is another gut com-
mensal that can have a profound influence on the balance of
T cells in the intestine and, potentially, systemically as well. Colo-
nization with SFB, which adhere tightly to intestinal epithelial
cells in the terminal ileum, was found to correlate with the pres-
ence of Th17 cells in the intestinal LP. Whereas LP Th17 cells
were absent in germ-free mice, they were abundant upon colo-
nization with SFB, and such mice were more resistant to growth
of C. rodentium (Ivanov et al., 2009). Colonization of mice with
SFB from a different source was reported to induce accumula-
tion of more diverse LP CD4+ T cells, including Th1, Th17, and
Treg cells (Gaboriau-Routhiau et al., 2009). The difference in
the influence of SFB between the two studies may be due to
differences in the bacterial strains employed or to genetic differ-
ences in the host. Mice engineered to express a human a-defen-
sin in intestinal epithelial Paneth cells displayed reduced
numbers of SFB and LP Th17 cells, but there was no effect on
Th1 cells, consistent with a specific influence of SFB on Th17
cell differentiation or accumulation in the LP (Salzman et al.,
2009) Together, these studies suggest that SFB contribute to
the balance of effector T cells (and potentially Treg cells) in the
LP and, hence, to the ability of the host immune system to main-
tain an effective barrier against potentially pathogenic microbes.
Although our understanding of how this barrier is regulated is
still rudimentary, there has been substantial recent progress.
Antimicrobial peptides (AMPs) produced by intestinal epithelial
cells in response to TLR signals have been shown to have critical
roles in protecting the host from damage mediated by patho-
genic bacteria such as vancomycin-resistant enterococcus
and Listeria monocytogenes (Brandl et al., 2007, 2008). AMPs
like the lectin RegIIIg are induced in Paneth cells upon coloniza-
tion of germ-free mice with commensal bacteria (Cash et al.,
2006) and hence serve to protect the mucosal barrier from
pathogens and resident commensals alike, reducing penetration
into the intestinal tissues and draining lymph nodes. Although
AMP expression can be induced directly by TLR signaling in
epithelial cells (Vaishnava et al., 2008), there is evidence that it
is also regulated indirectly, by IL-22 produced by Th17 cells
and other lymphoid cells in the LP. Mice deficient for IL-22 or
its upstream regulator, IL-23, were highly susceptible to infec-
tionwithC. rodentium, and this correlated with the loss of epithe-
lial-derived AMPs (Zheng et al., 2008). Colonization with SFB
correlated with elevated levels of RegIIIg and other AMPs and
with high-level production of the acute phase serum amyloid
A (SAA) proteins (Ivanov et al., 2009). However, there was no
apparent difference with or without SFB in IL-17 and IL-22
production by cells other than Th17 cells, which may explain
why SFB-deficient mice survive infection with C. rodentium.
This is consistent with the finding that protection from C. roden-
tium-induced lethality was observed even in the absence of
adaptive immunity (Zheng et al., 2008). Whether there are
specific commensal microbes that influence production of cyto-
kines by lymphoid cells other than Th17 cells is an important
issue that needs to be addressed.
The signaling pathways involved in commensal microbe-
induced accumulation of LP Th17 cells have not yet been eluci-
dated. Lumenal ATP can induce accumulation of Th17 cells in
germ-free mice, and it has been suggested that bacteria-derived
ATP activates a subset of intestinal dendritic cells (DCs) that, in
turn, produce Th17-inducing cytokines (Atarashi et al., 2008).
However, SFB induction of Th17 cells was independent of
ATP, and no single innate signaling pathway has yet been shown
to be required for accumulation of gut Th17 cells. DNA from
commensal bacteria has also been proposed to regulate the
Th17/Treg balance, presumably through activation of TLR9
(Hall et al., 2008). Paradoxically, although TLR9-deficient mice
had reduced proportions of both Th1 and Th17 cells and
increased Treg cells in the small intestine, there was no effect
in the absence of Myd88, which is required for signals down-
stream of most TLRs. Thus, individual TLRs may convey diver-
gent signals that influence the balance of T cells within the LP.The role of commensal microbes in regulating the balance of
pro- and anti-inflammatory cells is an important topic that has
only recentlybecomeamenable to investigationasaconsequence
of advances in genomic sequencing and taxonomic approaches
for classifying bacterial species. The recent discoveries outlined
above suggest that growth of pathogenic and commensal
bacteria is regulated by members of the commensal community
both directly, throughmechanisms like quorum sensing, and indi-
rectly, through signals in the host mucosal microenvironment.
For example, potentially pathogenic Clostridium difficile spores
germinate and undergo vegetative growth following treatment of
humans and experimental animals with antibiotics, presumably
due to the loss of bacterial inhibitory factors (Rupnik et al., 2009).
It is likely that a balance between Th17 and other effector T cell
types and Treg cells will impact the outcome, i.e., colitis versus
containment of bacterial growth.
The commensal microbiota have also been implicated in
having a key role in multiple tissue-specific autoimmune and
inflammatory diseases, although the evidence in human dis-
ease is largely anecdotal. Treatment with antibiotics has been
reported to ameliorate symptoms in a variety of autoimmune
diseases, from rheumatoid arthritis to Crohn’s disease and
multiple sclerosis (Guarner, 2007; Toivanen, 2003). Asthma is
a notable example in which there is a clear association of pro-
tection from the disease in individuals raised in rural environ-
ments, where there may be increased exposure to microbes
from farm animals (vonMutius, 2009). Treatment of experimental
animals with antibiotics or transfer into a germ-free environment
can result in either exacerbation or reduction in autoimmune
disease manifestation. In this regard, mice reared in a colony
with high levels of SFB may be predisposed to Th17-mediated
autoimmune diseases but may also be protected from other
inflammatory diseases through the beneficial activity of IL-22.
A more detailed understanding of how individual bacteria and
their products induce signaling pathways that influence host
immune system composition and responses may result in new
therapeutic approaches for strengthening mucosal immunity
and for attenuating inflammatory conditions.
In addition to commensal microorganisms, other environ-
mental factors can contribute to the differentiation of lymphoid
cells that mediate either proinflammatory or anti-inflammatory
functions. For example, xenobiotic agents, by inducing the
activity of Ahr, promote the differentiation of lymphoid cells
that produce inflammatory cytokines, particularly IL-22 (Veld-
hoen et al., 2008). Ahr ligands have also been reported to induce
expression of Foxp3 in T cells and to also increase transplanta-
tion tolerance by both direct and indirect influence on Treg cells
(Hauben et al., 2008; Quintana et al., 2008). However, in the
absence of Ahr, there were reduced levels of IL-17 and IL-22 in
intestinal Th17 and LTi cells, and mice were highly susceptible
to C. rodentium-mediated lethality (L. Zhou and D.R.L., unpub-
lished data). An attractive possibility is that microbial products
or metabolites generated in response to microbes act as ligands
to modulate Ahr activity and, hence, immune homeostasis.
Regulatory T Cells
Multiple immune cell subsets, including tolerogenic DCs, mye-
loid suppressor cells, NK-like T cells, IL-10-producing CD4+Cell 140, 845–858, March 19, 2010 ª2010 Elsevier Inc. 849
T cells, and B cells, and their products have been implicated
in inhibition of immune response-associated inflammation. It
appears that many of these cell types cause immunomodulation,
i.e., oppose the predominant pathogenic inflammatory
response, leading to mutual restraint. Over the last decade and
a half, Treg cells expressing the transcription factor Foxp3
have emerged as dedicated suppressors of diverse immune
responses and inflammation and vitally important keepers of
immune homeostasis. Mechanisms of peripheral tolerance
achieved through the activity of Treg cells complement deletio-
nal mechanisms of tolerance and anergy induction operating
both in the thymus and in the periphery.
The existence of a subset of T cells capable of limiting autoim-
munity and associated inflammation was unveiled by neonatal
thymectomy studies in mice, where chronic inflammation was
unexpectedly observed in various tissues. Subsequent work
revealed that autoimmunity accounted for the wide-spectrum
inflammatory lesions that included oophoritis, prostatitis, dia-
betes, thyroiditis, gastritis, myositis, and hepatitis. The autoim-
munity commencing in these mice was T cell dependent and
was averted by provision of T cells from euthymicmice (reviewed
in Sakaguchi and Sakaguchi, 2005). Furthermore, adoptive
transfers of naive CD4+ T cells into lymphopenic rodents impli-
cated this subset of T cells as culprits of immune mediated
lesions, most prominently colitis (Mason and Powrie, 1998).
Finally, a genetic study showed that, in mice expressing a trans-
genic TCR specific for myelin basic protein, a few T cells
expressing endogenously rearranged TCR prevented sponta-
neous EAE (Lafaille et al., 1994). This groundbreaking series of
experiments demonstrated that elimination or inactivation of
differentiating self-reactive thymocytes is incomplete and that
the thymus is a source of both pathogenic T cells that cause
autoimmunity and protective T cells. A subset of CD4+ T cells
expressing large amounts of high-affinity IL-2R a chain (also
known as CD25) was shown to provide potent suppression of
immune inflammation in neonatally thymectomized mice and in
lymphopenia-associated experimental models.
Identification of CD25 as a marker of Treg cells enabled their
isolation and facilitated characterization of their functional
properties in vitro and in vivo using adoptive cell transfers.
Unlike effector T cells, Treg cells failed to proliferate on their
own in response to TCR engagement but instead were able to
suppress proliferation of effector T cells in a contact-dependent
manner. Importantly, TCR-stimulated Treg cells also failed to
produce IL-2, but their survival and expansion was dependent
upon provision of IL-2 by activated effector T cells (Fontenot
et al., 2005a; Setoguchi et al., 2005). These observations
explained another old finding, that mice with targeted disrup-
tion of the Il2 gene exhibited a fatal lymphoproliferative autoim-
mune syndrome. Mice lacking IL-2Ra or IL-2Rb chains also
developed a similar syndrome that was rescued by transfer-
ring Treg cells or IL-2R-sufficient bone marrow (Malek, 2008).
These findings established an essential role for IL-2 in homeo-
stasis of Treg cells. They also suggested that activated effector
T cells and Treg cells are present at a certain equilibrium main-
tained by a simple negative regulatory loop—under physiologic
conditions activation of effector T cells associated with height-
ened IL-2 production is expected to increase the numbers850 Cell 140, 845–858, March 19, 2010 ª2010 Elsevier Inc.of suppressive Treg cells, which in turn limit effector T cell
response.
Since CD25 is upregulated upon activation of all effector
T cells, it was initially thought that, instead of being a distinct
T cell lineage, CD25+ Treg cells represent a metastable state
of T cell activation and that Treg cells function exclusively
by competing for IL-2 with recently activated effector T cells.
However, the discovery of Foxp3 and its role in Treg cells has
dispelled this view.Role of Foxp3 in Treg Cells
Positional cloning of the X chromosome gene encoding the
transcription factor Foxp3 in studies aimed at elucidation of
the genetic basis of the rare human autoimmune disorder
IPEX (Immune-dysregulation Polyendocrinopathy Enteropathy
X-linked) (Brunkow et al., 2001; Chatila et al., 2000; Fontenot
et al., 2003; Wildin et al., 2001) led to the discovery that Foxp3
is required for Treg cell differentiation and that its high expres-
sion is a characteristic feature of Treg cells (Fontenot et al.,
2003; Hori et al., 2003; Khattri et al., 2003). Loss-of-function
mutations in the Foxp3 gene result in fatal autoimmune lesions
affecting multiple tissues, reminiscent of the less severe inflam-
mation observed in neonatally thymectomized mice. IPEX
patients and Foxp3 mutant mice present with a variety of
immune and inflammatory lesions with a massive cytokine storm
including both Th1 and Th2 cytokines. In both mice and humans,
only mutant males are affected, whereas heterozygous female
carriers are spared because the latter harbor a normal popula-
tion of Treg cells expressing the wild-type Foxp3 allele due to
random X chromosome inactivation.
The possibility that the absence of Treg cells leads to a
systemic breakdown of immunological tolerance and uncon-
trolled inflammatory responses in Foxp3 mutant individuals has
been experimentally confirmed in a series of genetic studies.
First, analyses of the Foxp3 reporter mice have revealed
that Foxp3 expression is surprisingly restricted to a subset of
T cells with suppressor function (Fontenot et al., 2005b; Wan
and Flavell, 2005). High amounts of Foxp3 protein have not
been detected in other hematopoietic and nonhematopoietic
lineage cells (Fontenot et al., 2005b; Kim et al., 2009; Liston
et al., 2007). Evidence that the paucity of Treg cells accounts
for fatal autoimmune and inflammatory lesions associated with
the Foxp3 deficiency was provided by studies in which the adop-
tive transfer of Treg cells rescued disease in neonatal Foxp3-
deficient mice (Fontenot et al., 2003). Furthermore, mice with
T cell-specific and germline ablation of Foxp3were indistinguish-
able in the progression and severity of the autoimmune lesions
(Fontenot et al., 2005b).
The question of whether anti-inflammatory Treg suppressor
function is critical during the development of the immune system
or after the immune system is fully developed was addressed
through the analysis of Foxp3DTR knockin and Foxp3-DTR BAC
transgenic mice harboring an ‘‘ablatable’’ Treg population
expressing human diphtheria toxin receptor (Kim et al., 2007;
Lahl et al., 2007). Chronic ablation of Treg cells in adult Foxp3DTR
mice showed that Treg-mediated suppression is indispens-
able for preventing fatal lympho- and myelo-proliferative
inflammatory syndrome throughout the life spans of normal mice
(Kim et al., 2007).
Thymic and Peripheral Origin of Treg Cells
Neonatal thymectomy studies indirectly implicated the thymus
as a site of generation of Treg cells. Indeed, Foxp3+ cells with
suppressive function are found in the thymus. However, periph-
eral T cells can also acquire Foxp3 expression upon suboptimal
activation in a TGF-b-dependent manner (Chen et al., 2003).
Considering that intestinal commensal microbiota and food
represent the largest source of microbial inflammatory stimuli,
gut-associated lymphoid tissues are thought to be a main site
for generation of peripheral Treg (iTreg) cells. The generation of
iTreg cells is likely promoted by the environment rich in TGF-b
and retinoic acid, a combination that efficiently induces Foxp3
expression in antigen-stimulated T cells at the expense of
effector T cells, Th17 cells in particular (Mucida et al., 2007;
Sun et al., 2007; Coombes et al., 2007). Gut-resident DCs, distin-
guished by the expression of CD103, produce retinoic acid and
facilitate iTreg generation (reviewed in Coombes and Powrie,
2008). A delicate balance between inflammatory Th17 cells
and suppressive Treg cells in the gut microenvironment is illus-
trated by a number of mouse studies demonstrating that
a change in composition of the commensal flora leading to an
increase in Th17 cells in the gut is frequently associated with a
reciprocal decrease in Treg cells and vice versa (Ivanov et al.,
2008).These observations are in agreement with the in vitro
studies, which implicate a combination of high amounts of IL-6
and intermediate amounts of TGF-b in Th17 induction, whereas
high amounts of TGF-b alone facilitate iTreg differentiation
(Veldhoen et al., 2006; Zhou et al., 2008). Furthermore, many
Foxp3+ T cells in the gut express high amounts of RORg and
produce IL-17 (Zhou et al., 2008). Finally, genetic tagging of cells
using Cre recombinase expressed under the control of Foxp3
regulatory elements and a recombination reporter allele R26Y
(R26Y: loxP-flanked STOP cassette followed by a YFP-coding
sequence inserted into the ubiquitously expressed Rosa26
locus) showed that at least a quarter of IL-17-producing cells
expressed Foxp3 at some point in their history (Zhou et al.,
2008). These results speak strongly of a close relationship
between iTreg and Th17 cells and suggest that they might repre-
sent alternative cell fates.
Differentiation of Treg Cells
Thymic induction of Foxp3 requires TCR signaling of increased
strength (reviewed in Hsieh and Rudensky, 2005). Besides
TCR, engagement of common g-chain (gc) cytokine receptors,
foremost IL-2R, is required for both thymic and peripheral
generation of Treg cells (Vang et al., 2008; Fontenot et al.,
2005a). According to a two-step model of Treg differentiation,
TCR engagement first leads to CD25 upregulation making
precursor cells receptive to receiving IL-2 signals leading to
Stat5 activation (Lio and Hsieh, 2008; Burchill et al., 2008).
Finally, CD28 signaling induced upon binding of its ligands
CD80 and CD86 has also a cell-intrinsic role in Foxp3 induction
in the thymus (Salomon et al., 2000; Tai et al., 2005). Activation of
these signaling pathways leads to recruitment of a number of
transcription factors including NFAT, cRel, Creb, and Stat5 tothe promoter and several conserved noncoding regulatory ele-
ments of the Foxp3 gene and its expression (Kim and Leonard,
2007; Long et al., 2009; Zheng et al., 2010). Unexpectedly, acti-
vation of the PI3K-Akt pathway opposes Foxp3 induction in the
thymus (Haxhinasto et al., 2008; Josefowicz et al., 2009; Sauer
et al., 2008). Since Akt-mediated phosphorylation is known to
inactivate Foxo, it is possible that Foxo family members also
contribute to Foxp3 induction or survival of Foxp3-expressing
thymocytes.
As mentioned above a distinguishing feature of iTreg genera-
tion is its dependence upon TGF-bR signaling. The latter might
facilitate Foxp3 expression in more than one way. First, TGF-b
restrains recruitment of Dnmt1, the key maintenance DNA
methyltransferase whose activity likely leads to silencing of the
newly induced Foxp3 gene (Josefowicz et al., 2009). Second,
TGF-bR signaling leads to Smad recruitment to a conserved
noncoding element within the Foxp3 locus (Tone et al., 2008).
The ablation of this element in mice impairs iTreg induction,
whereas thymic Treg differentiation is unaffected (Zheng et al.,
2010). Unexpectedly, Th17 cell numbers do not change in
the gut-draining mesenteric lymph nodes or gut-associated
lymphoid tissues in thesemice, which remain free of unprovoked
inflammation in the intestines or elsewhere. Increased numbers
of Foxp3CD4+ T cells producing the immunomodulatory cyto-
kine IL-10, known as Tr1 cells, might compensate for a paucity
of iTreg cells and maintain immune homeostasis in the gut
(Zheng et al., 2010). Thus, suppressive Tr1 and iTreg cells might
also represent alternative fates of T cell differentiation in the gut
(Figure 2). Single-cell analysis of the precursor-product relation-
ship between iTreg, Th17, and Tr1 cells is needed to inform the
mechanisms regulating the delicate balance between inflamma-
tory and suppressive T cell lineages in the gut tissues.
Foxp3-Dependent Transcriptional Program
Once expressed, Foxp3 orchestrates distinct gene expression
and functional programs by amplifying and making permanent
the features of precursor cells that are beneficial to Treg function
and homeostasis, while obviating those that are detrimental
(Gavin et al., 2007). The ‘‘opportunistic’’ character of Foxp3-
dependent Treg cell differentiation has been revealed by com-
parison of cells isolated from healthy heterozygous female
mice that express Foxp3 reporter null and functional alleles
(Gavin et al., 2007; Lin et al., 2007). The former cells are exposed
to signals inducing Foxp3 yet lack Foxp3 protein. Although the
expression pattern of a sizable gene cluster in these ‘‘Foxp3-
less’’ ‘‘wannabes’’ and some of their functional properties
resemble those of Foxp3+ Treg cells, they fail to suppress.
In addition, Foxp3 confers proliferative potential and metabolic
fitness to Treg precursors (Gavin et al., 2007). Finally, Foxp3
enforces repression of immune response effector cytokines.
For example, cells expressing a Foxp3 reporter null allele pro-
duce high amounts of IL-17, whereas Foxp3+ Treg cells do not
(Gavin et al., 2007). In agreement with these results, expression
of a hypomorphic Foxp3 allele results in a marked impairment of
suppressor function of Treg cells and in their production of IL-4
(Wan and Flavell, 2005). Genome-wide analyses of Foxp3-
binding genes have suggested that Foxp3 acts as a transcrip-
tional repressor and activator and its binding is accompaniedCell 140, 845–858, March 19, 2010 ª2010 Elsevier Inc. 851
Figure 2. Possible Relationship between
Precursors Differentiating into Proinflam-
matory and Protective T Cells in the
Gut Microenvironment from Activated
Precursor T Cell Populations
Signals initiated by interaction of microbiota and,
potentially, pathogenic bacteria with epithelium
and dendritic cells result in production of diverse
cytokines that influence T cell differentiation.
The relative amounts of IL-6, TGF-b, retinoic
acid, and additional cytokines skew differentiation
of highly inflammatory Th17 or anti-inflammatory
Foxp3+ iTreg cells or IL-10-producing Foxp3
Tr1 cells in several possible ways: (A) Single
precursor can commit to any one of the three cell
fates under the influence of a particular cytokine
combination. (B) Suppressive iTreg and Tr1 cells
represent alternative cell fates, whereas proin-
flammatory Th17 cells originate from a distinct
pool of cells. (C) The three T cell fates originate
from separate activated precursor T cells. Addi-
tional studies are needed to clarify the relationship
between the three cell lineages.by corresponding inhibitory or permissive histone modifications
in the target genes (Marson et al., 2007; Zheng et al., 2007).
Stability of Foxp3 Expression and Treg Lineage
Despite epigenetic marking of target genes repressed or
induced by Foxp3, its ablation in mature, fully differentiated
Treg cells results in eventual loss of suppression and reversal
of the Foxp3-dependent transcriptional signature to that of
activated T cells or Treg ‘‘wannabes’’ (Williams and Rudensky,
2007). Thus, continuous expression of Foxp3 is required for
the maintenance of the developmentally established Treg func-
tional program. This feature is likely not unique to Treg cells as
ablation of Pax5, a key transcription factor in the B cell lineage,
results in a loss of B cell identity and dedifferentiation of B cells
into T cells (Cobaleda et al., 2007).
Importantly, ‘‘former’’ Treg cells devoid of Foxp3 differentiate
into effector T cells and cause pronounced tissue inflammation
upon transfer into lymphopenic recipients (Williams and Ruden-
sky, 2007). The observed pathology is likely due to activation of
‘‘former’’ Treg cells driven by self-reactive TCRs. These results
raise a question as to the stability of Foxp3 expression in Treg
cells and, therefore, of the Treg lineage. The possibility that
Treg cells represent an intrinsically unstable lineage and may
serve as a ‘‘fifth column’’ aiding, rather than opposing, inflamma-
tion has also a significant practical interest as Treg cell therapies
and drugs enhancing production of Treg cells are being consid-
ered for treatment of autoimmune diseases and for preventing
transplant rejection.
Under what circumstances might Treg cells lose their identity?
One obvious possibility is that the inflammatory environment852 Cell 140, 845–858, March 19, 2010 ª2010 Elsevier Inc.might favor ‘‘conversion’’ of Treg cells
into effector T cells. Specifically, in the
presence of high amounts of IL-6, the
Foxp3+ Treg cell population might
become Th17 cells (Xu et al., 2007;Yang et al., 2008a). A striking example of acquisition of charac-
teristic Th1 effector cell features by Treg cells has been recently
reported in a study of lethal Toxoplasma infection in mice
(Oldenhove et al., 2009). Furthermore, adoptive transfer of
Foxp3+ Treg cells into lymphopenic hosts also leads to a loss
of Foxp3 expression and their differentiation into so-called follic-
ular T helper cells (TFH) in Peyer’s patches (Tsuji et al., 2009). TFH
cells have recently emerged as principal assistants of B cell
responses in the germinal centers. These observations were
in line with the results of recent experiments utilizing a R26Y
recombination reporter allele combined with a Foxp3 BAC trans-
gene-expressing Cre recombinase. This study suggested that
a considerable proportion of YFP-tagged cells might have lost
Foxp3 expression and are able to produce proinflammatory
cytokines, most prominently IFN-g, and become pathogenic
under certain circumstances (Zhou et al., 2009).
On the other hand, adoptive transfer of CD25+CD4+ Treg cells
into recipients with a full lymphoid compartment did not lead to
a loss of Foxp3 expression (Floess et al., 2007; Komatsu et al.,
2009). In agreement with these results, another study has shown
that the majority of Treg cells expressing high amounts of CD25,
a direct transcriptional target of Foxp3, are stable and do not
lose Foxp3 upon adoptive transfer into lymphopenic hosts,
whereas a relatively minor fraction of CD25 or CD25loFoxp3+
T cells can lose Foxp3 expression and divert into effector T cell
lineages (Komatsu et al., 2009).
Thus, the issue of Treg lineage stability versus plasticity
remains controversial and awaits further experimentation.
In this regard, we would like to posit that the instability of
Foxp3 expression in ‘‘transitional’’ cells, some of which are on
Figure 3. Integration of Environmental Cues by Proinflammatory
Effector T Cells and Anti-inflammatory Treg Cells in the Gut
Cytokine microenvironment impacted by the gut microbiota promotes Stat3
phosphorylation, which in turn induces differentiation of activated T cells into
Th17 effector cells. At the same time, Stat3 phosphorylation endows Foxp3+
Treg cells with the ability to suppress Th17 responses and associated
inflammation.their way to becoming Treg cells or to losing Foxp3 expression,
is hardly surprising. However, if fully differentiated Treg cells
exhibit intrinsically unstable Foxp3 expression, does this repre-
sent a failure of mechanisms enforcing Foxp3 stability or is there
a purposeful process for destabilizing Foxp3 expression?
Integration of Environmental Cues by Treg Cells
The diversity of inflammatory lesions and increased production
of Th1, Th2, and Th17 cytokines in Treg-deficient mice suggest
that under physiologic conditions Treg cells control different
types of immune responses and associated inflammation. These
observations also raise the question as to whether Treg cells
employ a single mechanism of suppression or their function is
tailored to suppress a particular type of inflammation.
Indirect support for the latter possibility comes from reports
that acquisition of tissue-specific homing capability, including
cytokine-driven upregulation of appropriate chemokine recep-
tors, is important for the ability of Treg cells to suppress inflam-
mation in a given tissue (Siegmund et al., 2005; Siewert et al.,
2007). If Treg cells acquire the capacity to suppress a particular
type of inflammation in response to environmental cues that elicit
it (e.g., to upregulate a chemokine receptor shared between
effector and Treg cells), one may expect that some of the tran-
scription factors driving differentiation of inflammatory cells
would also be required for their restraint by Treg cells. In agree-
ment with this concept, IRF4, a transcription factor essential for
Th2 and Th17 cell differentiation, is expressed in Treg cells in
a Foxp3-dependent manner and is required for Treg-mediated
suppression of fatal Th2-mediated inflammation and hyper-IgE
syndrome (Zheng et al., 2009). Likewise, Treg cells devoid of
Stat3, whose activation is required for Th17 cell differentiation,
fail to restrain fatal colitis instigated by a dysregulated Th17
response. However, Stat3-deficient Treg cells exercise full
control over Th1 and Th2 responses, IL-2 production, and lym-
phoproliferation (Chaudhry et al., 2009) (Figure 2). Finally, both
effector T cells and Treg cells upregulate the signature Th1 tran-
scription factor, T-bet, in response to IFN-gR/Stat1 activation. In
Treg cells, T-bet induction is required for efficient homing to the
Th1 response site and for Treg survival and expansion and, thus,
for efficient suppression of Th1 responses (Koch et al., 2009).
These data imply functional heterogeneity within peripheral
Treg populations in terms of Treg cell states or subsets able to
suppress different types of inflammation (Figure 3). How do
these Treg cell subsets mediate suppression of a given type of
inflammation and how stable are they? Although the answer to
the second question is lacking, a few clues in response to the
first one have started to emerge. At least some effector T cell-
specific transcription factors modulate Foxp3-dependent tran-
scriptional programs in part by being recruited into Foxp3
complexes (Zheng et al., 2009; Chaudhry et al., 2009). As a result,
the ‘‘tuned’’ Treg cells upregulate distinct sets of chemokine and
cytokine receptors in a pattern matching that of the immune
effector cells. While chemokine receptors such as CCR6 or
CXCR3 likely facilitate spatial proximity of suppressive Treg
and inflammatory effector cells, cytokine receptors (e.g., ST2,
IL-1R, IL-6R) may act as a ‘‘sink’’ competing for important
factors and, thereby, limiting activation or differentiation of
effector cells (Koch et al., 2009; Chaudhry et al., 2009; Zhenget al., 2009). As discussed above, activation of effector T cell-
specific transcription factors in Treg cells may also confer the
ability to survive and expand and to elaborate a mechanism(s)
of suppression corresponding to a particular type of inflamma-
tion.
The observed ‘‘symmetry’’ in requirements for certain tran-
scription factors for eliciting a particular inflammatory response
and Treg-mediated suppression of this response may represent
a general principle of coordinated regulation of gene expres-
sion in different cell types in response to extracellular stimuli.
We suggest that formation of transcriptional complexes between
cell type-specific, function-defining transcription factors (e.g.,
Foxp3) and activation-dependent transcription factors acting
as environmental sensors (e.g., Stat3), or their cooperative
binding to DNA, form the basis for such regulation. This concept
is further propped by the observation that Treg cells found in
the fat pads exhibit a distinct gene expression signature that
includes a subset of genes characteristic of adipocytes and
are able to keep sterile inflammation and associated glucose
intolerance in check. The distinct features of ‘‘fat’’ Treg cells
are likely elicited by the unique environmental factors, which
include adipokines and other products of adipocytes (Feuerer
et al., 2009a). We suggest that similar ‘‘tuning’’ of Treg and other
immune cell types by the environment is not limited to fat pads
but extends to other types of tissues.Cell 140, 845–858, March 19, 2010 ª2010 Elsevier Inc. 853
Uncovering modules of transcriptional regulation in Treg cells
and their associated functions in different inflammatory and
tissue settings will facilitate understanding of mechanisms of
suppression and likely inform novel means of selective thera-
peutic intervention for inflammatory disorders of different origins.
Suppression Mechanisms and Their Cellular Targets
Despite intensive investigation, mechanisms of Treg-mediated
suppression remain relatively obscure. Until recently, it was
unclear whether a single or multiple mechanisms are employed
by Treg cells to curb inflammatory responses and how redun-
dant such mechanisms might be. Another important question
has been the identity of cell types serving as targets of Treg-
mediated suppression. Ablation of Treg cells in adult healthy
mice results in proliferation and activation of multiple immune
cell types including NK cells, T and B cells, DCs, granulocytes,
macrophages, and monocytes (Kim et al., 2007). Furthermore,
activation of T cells, DCs, and NK cells occurs very early after
Treg ablation suggesting that Treg cells might directly suppress
these cells (Feuerer et al., 2009b; Kim et al., 2007). Although
simultaneous elimination of Foxp3+ Treg and effector CD4+
T cells prevents both lympho- and myelo-proliferative syn-
dromes, DC activation is still observed. This finding implies
that activation of self-reactive CD4+ T cells, normally restrained
by Treg cells, fuels expansion of activated myeloid and lymphoid
cells and the resulting inflammation (Kim et al., 2007; Kim and
A.Y.R., unpublished). In vitro Treg cells efficiently suppress
activation of T and B cells, NK cells, and DCs (Zhao et al.,
2006; Shevach, 2009). However, intravital imaging studies have
thus far failed to reveal selective (i.e., nonrandom) Treg and
effector T cell interactions, whereas stable Treg-DC contacts
were readily observed (Tadokoro et al., 2006; Tang et al.,
2006). Together, existing data suggest that DCs and potentially
NK cells serve as direct targets of Treg cells in vivo. It seems
likely that a number of other cell types of hematopoietic and
nonhematopoietic origin can also be kept in check by Treg cells.
Consistent with this idea are reported inhibitory effects of Treg
cells on inflammatory and metabolic properties of adipocytes,
suggesting that they may limit metabolic causes and conse-
quences of inflammation and associated pathologies like type
II diabetes (Feuerer et al., 2009a).
Considering that multiple cell types serve as targets of Treg-
mediated suppression and distinct transcription factors par-
take in Treg mediated suppression of different types of inflam-
mation, it seems likely that Treg cells utilize multiple means of
restraining inflammation. In fact, Treg-restricted inactivation of
the immunosuppressive cytokine IL-10 resulted in increased
inflammation at major environmental interfaces, with late-onset
colitis, but not in the systemic autoimmunity characteristic of
mice lacking Treg cells (Rubtsov et al., 2008). In addition to
IL-10, TGF-b and the newly described cytokine IL-35 have
been implicated in restraining inflammation in the colon (Collison
et al., 2007).
In addition to cytokine-mediated modulation of inflammatory
responses, Treg cells display high amounts of CTLA4 and TIGIT,
two Ig family members that are able to inhibit the immunostimu-
latory potential of DCs by reducing expression of the costimula-
tory molecules CD80 and CD86 and by inducing IL-10 produc-854 Cell 140, 845–858, March 19, 2010 ª2010 Elsevier Inc.tion in DCs, respectively (Wing et al., 2008; Wing and
Sakaguchi, 2009; Yu et al., 2009). Furthermore, a yet unknown
mechanism enables Treg-mediated suppression of extracellular
thiol release by DCs that supports effector T cell proliferation
(Yan et al., 2009).
Small molecules elaborated by Treg cells have also been
implicated in restraining inflammation. Specifically, Foxp3-
dependent expression of the ectonucleotidases CD39 and
CD73 endows Treg cells with the ability to sequentially convert
highly inflammatory extracellular ATP, which accumulates under
hypoxic conditions, into adenosine via an AMP intermediate
(Deaglio et al., 2007). Adenosine binding to A2A and A2B recep-
tors on lymphocytes and myeloid cells leads to their inactivation,
at least in part due to an increase in intracellular cAMP (Sitkov-
sky, 2009; Sitkovsky et al., 2004). It has been also suggested
that Treg cells directly extrude cAMP, which is transported
through the gap junctions into the effector T cells (Bopp et al.,
2007). However, formation of gap junction requires stable cell-
cell contacts between Treg and effector T cells, which have
not been demonstrated so far.
Besides immunomodulation or inactivation, perforin- and
granzyme-mediated cytolysis of immune effector and accessory
cells by Treg cells has been considered as a means of suppres-
sion (Cao et al., 2007; Gondek et al., 2005; Grossman et al.,
2004). In addition to direct killing, an indirect way of elimination
of effector T cells is through induction of apoptosis due to
a growth factor withdrawal. In this regard, Treg cells are able
to deprive effector T cells of IL-2 due to a much higher level of
CD25 expression (Pandiyan et al., 2007).
Concluding Remarks
Although we briefly overviewedmanymeans of suppression em-
ployed by Treg cells, the list of putative suppressor mechanisms
will undoubtedly continue to grow. We would like to emphasize
that no single mechanism of suppression can account for
expansive Treg functions in regulation of autoimmune and auto-
inflammatory states, allergic and metabolic inflammation, tissue
injury, immunity to infection, and tumorigenesis. The diversity
of effector mechanisms affords versatility to a Treg-mediated
suppression program capable of restraining diverse types of
inflammatory responses in different tissues. Likewise, functions
of Th17 cells, a prototypic inflammatory T cell type, are most
likely not limited to production of IL-17 or IL-22. Both Treg and
Th17 cells can exert both beneficial and pathogenic effects
depending on a particular biological setting. The intricate
mechanisms governing differentiation and functions of these
pro- and anti-inflammatory cells speak to major challenges
ahead—the need to dissect the fine balance between innate
and adaptive pro- and anti-inflammatory cells in the context of
their complex relationships with infectious agents and com-
mensal microbiota.
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